Boehringer supports the pharmacist as a key actor in monitoring chronic hypertensive.

– in this area, the pharmacist assumes a fundamental role in the chain of the national health system, for his support and proximity with the chronic patient, such as hypertensive subjects, and monitoring of its adherence to treatments

-Boehringer Ingelheim, as a sign of its commitment to contribute to the improvement of health care processes and patient care, collaborates on the day for community pharmacists the SEFAC has organized in the framework of the 18th meeting of the SEH-LEHLA

– among other activities, the Conference has included theoretical and practical workshops, presentation of research projects in high blood pressure and a panel discussion among health professionals

Valencia, March of 2013.- during the 6th to March 8 Spanish Hipertension-liga Spanish society to fight hypertension (SEH-LELHA) has held its 18th annual meeting in Valencia.

In the framework of this important event, for the first time has taken place a specific day for community pharmacists, in which Boehringer Ingelheim has worked and which has been organized by the Spanish society of community pharmacy (SEFAC).

About 40% of the adult population has hypertension, a health problem of first level that must allocate substantial resources to control its risks and complications. In this condition, as in all chronic diseases, it is essential for patients to become aware of the importance of complying with their treatment, the risks of the lack of follow-up of taking the medication and what this entails in its health and health spending.

And, precisely, in this area, the pharmacist assumes a fundamental role within the chain of the national health system, for his support and proximity with the chronic patient, such as hypertensive subjects, and monitoring of its adherence to treatments.

One of the central elements of the culture of Boehringer Ingelheim is its commitment to the health and well-being of society. Therefore, the company promotes plans for education, outreach and awareness aimed at patients and society in general.

This strategy is based on the commitment and orientation towards the chronic patient, through education in stewardship, awareness of the importance of prevention and knowledge of their disease and treatment and adherence, among other programs.

The objective of this Conference was to progress in this field. The Presidents of the SEFAC, Jesús C. Gómez, and the SEH-LEHLA, the doctor Nieves Martell, among other experts, have been responsible for open this meeting which included a panel discussion on comprehensive coordination of different professionals in primary care for the care of the patient with cardiovascular risk, theoretical practical workshops on map (ambulatory monitoring of the) Blood pressure), chronotherapy in hypertension (AHT) approach and the stratification of cardiovascular risk in community pharmacy. In addition, there have been several research projects related to the hypertension and vascular risk, as MEPAFAC (measurement of blood pressure in adolescents by community pharmacists), and MICOEDS (improvement of compliance with health education from community pharmacy in coordination with primary care).

Combat the lack of adherence

Adhesion is defined as adequate awareness of the patient of its importance and good compliance with treatment, which means the medication strictly as directed by health professionals and not abandon treatment before finalizing them. The non-adherence to medical treatment – it relates with more admissions – and a worse disease control is a very important problem in our societies that affects more than half of the patients and that is growing with the treatment time being higher in chronic patients. In Spain it is estimated that you between 30% and 50% of the patients abandoned treatment in the first 6 months and of these, only 30% stop taking it by forgetfulness or factors not intencionados1. Therefore, combat the lack of adherence is one of the greatest challenges for health professionals.

Boehringer Ingelheim add value through innovation ”

The Boehringer Ingelheim group is one of the 20 biggest in the world pharmaceutical companies. Headquartered in Ingelheim, Germany, it works globally with 145 affiliated and has over 44,000 employees. Since its founding in 1885, the family-owned company is committed to the research, development, production and marketing of new products of high therapeutic value for human and animal.

A central element of the corporate culture of Boehringer Ingelheim is committed to socially responsible action. For this reason, the company participates in social projects and take care of their collaborators and families, offering everyone equal opportunities. Respect, equal opportunities and the reconciliation of working life and the family constitute the basis of mutual cooperation. As well as the protection of the environment and sustainability that are always present in any activities of Boehringer Ingelheim.

Boehringer Ingelheim settled in Spain in 1952, and over the past 50 years has evolved to be in position No. 10 of the pharmaceutical sector in our country. The company is headquartered in Spain in Sant Cugat del Vallès (Barcelona), and has two international centers of production at Malgrat de Mar and Sant Cugat del Vallès.

References

1 Dr. John Weiman. Lecture 17 January 2012, Madrid: how and why the patients plant endangered their lives intentionally .